Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News scPharmaceuticals Inc SCPH

Healthcare
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead... see more

Recent & Breaking News (NDAQ:SCPH)

scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update

GlobeNewswire January 30, 2023

scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer

GlobeNewswire December 19, 2022

scPharmaceuticals to Participate in the 12th Annual LifeSci Partners Corporate Access Event

GlobeNewswire December 14, 2022

scPharmaceuticals Announces Pricing of $50 Million Public Offering

GlobeNewswire November 22, 2022

scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock

GlobeNewswire November 21, 2022

scPharmaceuticals Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 9, 2022

scPharmaceuticals to Participate in the Jefferies London Healthcare Conference

GlobeNewswire November 2, 2022

scPharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022

GlobeNewswire October 26, 2022

UPDATE - scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure

GlobeNewswire October 10, 2022

scPharmaceuticals Announces $100 Million Debt Financing Agreement with Oaktree

GlobeNewswire October 10, 2022

scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure

GlobeNewswire October 10, 2022

scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting

GlobeNewswire September 30, 2022

scPharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 1, 2022

scPharmaceuticals Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire August 9, 2022

scPharmaceuticals Inc. to Participate in the Maxim Group LLC Late-Stage Advancements in Heart Failure Therapeutics and Management Panel Discussion

GlobeNewswire July 13, 2022

scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure

GlobeNewswire July 12, 2022

scPharmaceuticals Inc. to Host FUROSCIX® (furosemide) 80mg/10mL for Subcutaneous Administration Commercial Day: An Investigational Treatment for Heart Failure Patients

GlobeNewswire June 30, 2022

scPharmaceuticals Inc. Announces Abstracts Accepted for Presentation at the American Association of Heart Failure Nurses 18th Annual Meeting

GlobeNewswire June 7, 2022

scPharmaceuticals to Present at the Jefferies Healthcare Conference

GlobeNewswire May 24, 2022

scPharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire May 17, 2022